GSK gambles on massive heart drug trial

While other companies are cutting back, GlaxoSmithKline is ramping up. The drugmaker announced on Thursday that it is initiating the first Phase III clinical trial for an investigational Lp-PLA2

Survey says: Nissen or Rost for FDA Commish

Steven Nissen (photo) may be on Big Pharma's short list for the least desirable candidate for FDA Commissioner, but many apparently think its critics like him who should be at the top of the list.

Schering-Plough stock down on Vytorin sales

Schering-Plough's stock took a dive this week after the news spread that sales of its troubled cholesterol drugs dropped significantly in November, after stablizing in October. Schering-Plough

Targanta cuts jobs following FDA rejection

Targanta Therapeutics has decided to pull out the axe following the FDA's rejection of oritavancin, the company's experimental antibiotic for complicated skin and skin structure infections (cSSSI).

EMEA panel backs Lilly's prasugrel

Good news for Eli Lilly. While Lilly was holding its breath for a response from the FDA for its experimental drug, prasugrel, the company managed to gain an endorsement from an EMEA advisory panel.

Distributors may suffer from credit crunch

The big three U.S. drug distributors--Cardinal Health, McKesson and AmerisourceBergen--are heading into their seasonal year-end inventory ramp-up with less cash and tougher credit market conditions

Drug 'holidays' may make Tysabri safer

Hot on the heels of the announcement that another Tysabri patient had developed PML comes another bit of related news--one that could contain a ray of hope for managing the risk of brain infection

Is Amgen worth $61B to Pfizer?

Yesterday, Deutsche Bank analyst Barbara Ryan proposed a Pfizer-Amgen combo, becoming the third industry watcher to float that particular trial balloon. Today, BNet's Jim Edwards asks, "why not?" If

Sweden to probe AZ's Nobel ties

A Swedish anti-corruption prosecutor says he's launched a criminal probe of this year's Nobel Prize in medicine. Sparked by allegations that AstraZeneca influenced the choice of Harald zur

Health groups try to steer FDA choice

We already know about the heated speculation on the identity of the next FDA commissioner. Now let's talk about the behind-the-scenes lobbying. As the Wall Street Journal reports this morning, health

EU officials seize 34M counterfeit medicines

EU custom officers seized 34 million counterfeit or illegal medicines in a coordinated operation by all 27 states, officials reported earlier this week. The stepped-up effort, dubbed Medi-Fake, was

Pfizer finds buyer for Cork plant

Portuguese contract manufacturer Hovione has purchased Pfizer's Cork, Ireland facility for an undisclosed sum. Pfizer has been trying to find a buyer for the site--which manufactures intermediates

Colon cancer drug shortage raises concerns

There is not a large enough supply of a major colorectal cancer chemotherapy medication, Forbes reports today. The drug is leucovorin, an injectable generic chemotherapy medication, and the shortage

Texas sues J&J's Janssen Pharma

The state of Texas is suing Johnson & Johnson's Janssen Pharmaceuticals, alleging that the drug company used Texas mental health officials as "pitchmen" and carried out other unseemly tactics to

Jury trial granted to fired Amgen whistleblower

Darrell G. Dotson of Newbury Park will have his day in court and bypass Amgen's arbitration process, ruled Ventura County Superior Court judge, Henry Walsh. Amgen fired the former patent lawyer last

Ovation's drug price hike leads to lawsuit

Ovation Pharmaceuticals may be in hot water. The company, which dedicates itself to drugs for rare medical conditions, purchased the rights to Merck's Indocin in 2005, bought a rival drug in 2006 and

FDA mandates warnings for epilepsy meds

The U.S. Food and Drug Administration (FDA) is requiring warnings on a laundry list of antiepileptic medications that say that use of the drugs increases the risk of suicidal thoughts and behaviors.

Bristol-Myers will lay off yet another 10%

Bristol-Myers Squibb will be handing layoff notices to another 10 percent of its 37,000 remaining workers, likely due to weak pipelines, increasing regulatory burdens, looming generic competition and...

Abbott's TriCor follow-up gets FDA nod

Abbott shoots and it scores--finally. The FDA gave the OK to the company's TriLipix cholesterol drug, a follow-up to the highly successful TriCor, which is facing generic competition. The new med is

Generics makers: Canada's rules too tough

A two-year-old lawsuit that argues against rules governing the entrance of generics into the Canadian marketplace goes to a federal court today, with generics makers arguing for a shorter exclusivity